Last reviewed · How we verify

BF-200 ALA 3% — Competitive Intelligence Brief

BF-200 ALA 3% (BF-200 ALA 3%) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical photodynamic therapy agent. Area: Dermatology.

phase 2 Topical photodynamic therapy agent 5-aminolevulinic acid (ALA) synthase Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

BF-200 ALA 3% (BF-200 ALA 3%) — Biofrontera Bioscience GmbH. BF-200 ALA 3% is a topical cream used to treat actinic keratosis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BF-200 ALA 3% TARGET BF-200 ALA 3% Biofrontera Bioscience GmbH phase 2 Topical photodynamic therapy agent 5-aminolevulinic acid (ALA) synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical photodynamic therapy agent class)

  1. Biofrontera Bioscience GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BF-200 ALA 3% — Competitive Intelligence Brief. https://druglandscape.com/ci/bf-200-ala-3. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: